GleamWall
中文EN

CRMD CorMedix Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1410098 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY96.3%
TTM net income YoY-60.7%
TTM EPS YoY-71.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin77.0%
Operating margin38.3%
Net margin15.4%
FCF margin74.1%
EBITDA margin46.0%

Returns

ROE15.3%
ROA7.7%
ROIC (approx.)27.3%
Asset turnover0.50x

Leverage & solvency

Liabilities / assets49.7%
Debt / equity0.00x
Current ratio2.43x
Interest coverage—

Cash quality & payout

Operating cash flow / net income4.90x
Accruals ratio-29.8%
Payout ratio—
Capex / revenue1.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$311.71M$43.47M
Cost of revenue$22.09M$3.03M
Gross profit$275.75M$40.28M
R&D expense$19.33M$3.94M
SG&A expense$68.22M$29.96M
Operating income$150.14M-$22.36M
Interest expense$2.78M$36,000
Pretax income$150.02M-$19.32M
Income tax-$13.04M-$1.40M
Net income$163.06M-$17.93M
EBITDA$150.82M-$22.20M
EPS (basic)2.25-0.30
EPS (diluted)2.04-0.30
Weighted avg. shares (diluted)80,30858,872
Banking
Net interest income—$1.40M
Balance sheet
Cash & equivalents$144.84M$40.76M
Short-term investments$3.69M$11.04M
Receivables$171.23M$51.65M
Inventory$29.72M$7.60M
Current assets$367.05M$114.58M
PP&E, net$5.96M$1.83M
Goodwill$30.00M—
Intangibles$379.07M$1.84M
Total assets$826.14M$118.85M
Current liabilities$174.27M$33.84M
Long-term debt$150,000—
Total debt$150,000—
Total liabilities$420.83M$34.19M
Shareholders' equity$405.31M$84.66M
Net debt-$144.69M—
Shares outstanding79.26M64.41M
Cash flow statement
Operating cash flow$175.05M-$50.62M
Capital expenditure$2.26M$116,000
Free cash flow$172.79M-$50.73M
Investing cash flow-$308.43M$21.23M
Financing cash flow$238.45M$26.32M
Depreciation & amortization$677,000$154,000
Stock-based compensation$13.83M$6.13M

Free plan shows the latest 2 periods; Pro shows all 19 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.